Overview of Tigecycline Efficacy and Safety in the Treatment of Complicated Skin and Skin Structure Infections - A European Perspective

References

• Wilson SE. Clinical trial results with linezolid, an oxazolidi-none, in the treatment of soft tissue and postoperative Gram-positive infections. Surg Infect (Larchmt) 2001; 2: 25–35.
   PubMedGoogle Scholar
• Jones ME, Karlowsky JA, Draghi DC, Thornsberry C, Sahm DF, Nathwani D. Epidemiology and antibiotic susceptibil-ity of bacteria causing skin and soft tissue infections in the USA and Europe: a guide to appropriate antimicrobial therapy. Int J Antimicrob Agents 2003; 22: 406–419.
   PubMed Web of Science ®Google Scholar
• Kirby JT, Mutnick AH, Jones RN, Biedenbach DJ, Pfaller MA. Geographic variations in garenoxacin (BM5284756) activ-ity tested against pathogens associated with skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (2000). Diagn Microbiol Infect Dis 2002; 43: 303–309.
   PubMed Web of Science ®Google Scholar
• Projan SJ. Why is big Pharma getting out of antibacterial drug discovery? Curr Opin Microbiol 2003; 6: 427–430.
   PubMed Web of Science ®Google Scholar
• Nichols R. Optimal treatment of complicated skin and skin structure infections. J Antimicrob Chemother 1999; 44 (suppl A): 19-23.
   Google Scholar
• Archer GL. Staphylococcus aureus: a well-armed pathogen. Clin Infect Dis 1998; 26: 1179–1181.
   PubMed Web of Science ®Google Scholar
• Diekema D, Pfaller M, Schmitz F, Smayevsky J, Bell J, Jones R, et al. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region of the SENTRY antimi-crobial surveillance program, 1997-1999. Clin Infect Dis 2001; 32: S114–S132.
   PubMed Web of Science ®Google Scholar
• Moran GJ, Krishnadasan A, Gorwitz RJ, Fosheim GE, Mc-Dougal LK, Carey RB, et al. Methicillin-resistant S. aureus in-fections among patients in the emergency department. N Engl J Med 2006 355, 666–674.
   Google Scholar
• Staphylococcus aureus resistant to vancomycin-United States, 2002. MMWR Morb Mortal Wkly Rep 2002; 51: 565-567.
   Google Scholar
• Tenover FC, Biddle JW, Lancaster MV. Increasing resist-ance to vancomycin and other glycopeptides in Staphylococcus aureus. Emerg Infect Dis 2001; 7: 327–332.
   PubMed Web of Science ®Google Scholar
• Bouchillon SK, Hoban DJ, Johnson BM, Johnson JL, Hsi-ung A, Dowzicky MJ. In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004). Diagn Microbiol Infect Dis 2005; 52: 173–179.
   PubMed Web of Science ®Google Scholar
• Ruit AC, Florijn A, Verhoef J, Milatovic D. Presence of tetracycline resistance determinants and susceptibility to tigecy- cline and minocycline. Antimicrob Agents Chemother 2005; 49: 1636–1638.
   PubMed Web of Science ®Google Scholar
• Betriu C, Culebras E, Rodriguez-Avial I, Gomez M, Sanchez BA, Picazo JJ. In vitro activities of tigecycline against erythromycin-resistant Streptococcus pyogenes and Strepto-coccus agalactiae: mechanisms of macrolide and tetracycline re-sistance. Antimicrob Agents Chemother 2004; 48: 323–325.
   PubMed Web of Science ®Google Scholar
• Henwood CJ, Gatward T, Warner M, James D, Stockdale MW, Spence RP, et al. Antibiotic resistance among clinical iso-lates of Acinetobacter in the UK, and in vitro evaluation of tige-cycline (GAR-936). J Antimicrob Chemother 2002; 49: 479–487.
   PubMed Web of Science ®Google Scholar
• Petersen PJ, Bradford PA, Weiss WJ, Murphy TM, Sum PE, Projan SJ. In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other re-sistant Gram-positive pathogens. Antimicrob Agents Chemother 2002; 46: 2595–2601.
   PubMed Web of Science ®Google Scholar
• Methods for antimicrobial susceptibility testing of anaero-bic bacteria: approved standard.), 5th ed. NCCLS document. M11-A15. National Committee for Clinical Laboratory Stan-dards, Wayne, PA, 2001.
   Google Scholar
• Methods for dilution antimicrobial susceptibility tests for microbes that grow aerobically; approved standard), 6th ed. Na-tional Committee for Clinical Laboratory Standards, Wayne, PA, 2003.
   Google Scholar
• Performance standards for antimicrobial disk susceptibility tests; approved standard.), 8th ed. National Committee for Clin-ical Laboratory Standards, Wayne, PA, 2003.
   Google Scholar
• Muralidharan G, Micalizzi M, Speth J, Raible D, Troy S. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother 2005; 49: 220–229.
   PubMed Web of Science ®Google Scholar
• Sesoko S, Umemura K, Nakashima M. Pharmacokinetics (PK), safety, and tolerability of tigecycline (GAR-936) in healthy Japanese males. In Abstracts of the 42nd Interscience Confer-ence Antimicrobial Agents and Chemotherapy 2002: Abstract A1403.
   Google Scholar
• Murray J, Wilson S, Klein S, Yellin A, Loh E. The clinical response to tigecycline in the treatment of complicated intra-ab-dominal infections in hospitalized patients. A phase 2 clinical trial. In Abstracts of the 43rd Interscience Conference on An-timicrobial Agents and Chemotherapy 2003: Abstract L739.
   Google Scholar
• Postier RG, Green SL, Klein SR, Ellis-Grosse EJ, Loh E, 200 Group. A multicenter, randomized, open-label safety and ef-ficacy study of tigecycline dosages for complicated skin and skin structure infections in hospitalized patients. Clin Therapeut 2004; 26: 704–714.
   Google Scholar
• Ellis-Grosse EJ, Babinchak T, Dartois N, Rose G, Loh E. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 com-parison studies with vancomycin-aztreonam. Clin Infect Dis 2005; 41, Suppl 5: S341–353.
   PubMed Web of Science ®Google Scholar
• Babinchak T, Ellis-Grosse E, Dartois N, Rose GM, Loh E. The efficacy and safety of tigecycline for the treatment of com-plicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 2005; 41, Suppl 5: S354–367.
   Web of Science ®Google Scholar
• National Cancer Institute. Common Terminology Criteria for Adverse Events. 2006 V3 http://ctep.cancer.gov/forms/CT-CAEv3.pdf Accessed on: 10 March 2007.
   Google Scholar
• Nord CE, Sillerstrom E, Wahlund E. Effect of tigecycline on normal oropharyngeal and intestinal microflora. Antimicrob Agents Chemother 2006; 50: 3375–3380.
   PubMed Web of Science ®Google Scholar
• Wilcox MH, Freeman J. Analysis of reports of Clostrid-ium difficile infection in phase 2 and 3 studies of tigecycline In Abstracts of the European Conference on Clinical Microbiology and Infectious Diseases, Munich, Germany, 2007; Poster 1683.
   Google Scholar
• Baines SD, Saxton K, Freeman J, Wilcox MH. Tigecycline does not induce proliferation or cytotoxin production by epidemic Clostridium difficile strains in a human gut model. J Antimicrob Chemother 2006; 58: 1062–1065.
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Palatnick L, Nichol KA, Low DE, Hoban DJ. Antimicrobial resistance in Haemophilus influenzae and Moraxella catarrhalis respiratory tract isolates: Results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob Agents Chemother 2003; 47: 1875–1881.
   PubMed Web of Science ®Google Scholar
• Wilson SE, Solomkin JS, Le V, Cammarata SK, Bruss JB. A severity score for complicated skin and soft tissue infections derived from phase III studies of linezolid. Am J Surg 2003; 185: 369–375.
   PubMed Web of Science ®Google Scholar
• Holmberg SD, Solomon SL, Blake PA. Health and eco-nomic impacts of antimicrobial resistance. Rev Infect Dis 1987; 9: 1065–1078.
   PubMedGoogle Scholar
• Fejfarova V, Jirkovska A, Skibova J, Petkov V. [Pathogen resistance and other risk factors in the frequency of lower limb amputations in patients with the diabetic foot syndrome]. Vnitr Lek 2002; 48: 302–306.
   PubMedGoogle Scholar
• Roberts S, Chambers S. Diagnosis and management of Staphylococcus aureus infections of the skin and soft tissue. In-tern Med J 2005; 35, Suppl 2: S97–105.
   Google Scholar
• Gordon SM. Antibiotic prophylaxis against postoperative wound infections. Cleve Clin J Med 2006; 73, Suppl 1: S42–45.
   PubMedGoogle Scholar
• Elston DM. Community-acquired methicillin-resistant Staphylococcus aureus. J Am Acad Dermatol 2007; 56: 1–16; quiz 17-20.
   PubMed Web of Science ®Google Scholar
• Cosgrove SE, Qi Y, Kaye KS, Harbarth S, Karchmer AW, Carmeli Y. The impact of methicillin resistance in Staphylococ-cus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect Control Hosp Epidemiol 2005; 26: 166–174.
   PubMed Web of Science ®Google Scholar
• Lodise TP, McKinnon PS. Clinical and economic impact of methicillin resistance in patients with Staphylococcus aureus bacteremia. Diagn Microbiol Infect Dis 2005; 52: 113–122.
   PubMed Web of Science ®Google Scholar
• Greiner W, Rasch A, Kohler D, Salzberger B, Fatkenheuer G, Leidig M. Clinical outcome and costs of nosocomial and com-munity-acquired Staphylococcus aureus bloodstream infection in haemodialysis patients. Clin Microbiol Infect 2007; 13: 264–268.
   PubMed Web of Science ®Google Scholar
• Livermore DM. Tigecycline: what is it, and where should it be used? J Antimicrob Chemother 2005; 56: 611–614.
   PubMed Web of Science ®Google Scholar